Abbvie Inc Stock Price, News & Analysis

AbbVie announced the European Commission's approval of SKYRIZI (risankizumab) as the first IL-23 inhibitor for treating adults with moderately to severely active Crohn's disease. This approval, significant for patients with inadequate responses to other therapies, is supported by the Phase 3 ADVANCE, MOTIVATE, and FORTIFY studies. Results indicated that patients on SKYRIZI showed better clinical remission and endoscopic response rates at both 12 and 52 weeks compared to placebo. The treatment is integral to AbbVie's growing IBD portfolio, aiming to alleviate symptoms and improve patient outcomes.

AbbVie (NYSE: ABBV) will present nearly 65 abstracts, including 15 oral presentations, at the upcoming American Society of Hematology (ASH) annual congress from December 10-13, 2022. The presentations will cover 8 types of blood cancers, highlighting investigational and approved therapies such as epcoritamab and navitoclax. Data aims to showcase advancements in treating chronic lymphocytic leukemia and multiple myeloma. The company emphasizes a commitment to improving patient outcomes in blood cancers, although many therapies are still under evaluation and not yet approved.

AbbVie (NYSE: ABBV) will present at the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022, at 8:30 a.m. Central time. Key executives, including Rob Michael and Scott Reents, will participate. A live audio webcast of the presentation will be available on AbbVie's Investor Relations website, with an archived version accessible later that day. AbbVie focuses on innovative medicines across therapeutic areas such as immunology and oncology.

AbbVie celebrated its fourth annual BOTOX® Cosmetic Day, achieving record-breaking participation and sales. The event marked the highest single treatment day in the brand's 20-year history, with over 285,000 site visitors within the first hour. Allē registrations hit a new peak, and BOGO gift cards sold out, exceeding 2021 sales by 20%. The brand experienced a 130% increase in searches for local providers. These metrics reflect heightened consumer interest and satisfaction with BOTOX® Cosmetic, which remains the only FDA-approved treatment for specific facial lines.

On November 9, 2022, AbbVie (NYSE: ABBV) announced its participation in the 4th Annual Wolfe Research Healthcare Conference scheduled for November 15, 2022, at 10:30 a.m. CT. Key executives, including Rob Michael and Jeffrey Stewart, will present virtually. A live audio webcast will be available on AbbVie's Investor Relations website, with an archived session accessible later that day. AbbVie focuses on innovative medicines in various therapeutic areas, such as immunology, oncology, and neuroscience.

AbbVie (NYSE: ABBV) will present 36 abstracts at the American College of Rheumatology's annual meeting (ACR Convergence 2022), highlighting advancements in treatments for rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. Key data includes long-term safety analyses for RINVOQ® (upadacitinib) and SKYRIZI® (risankizumab). Notable presentations cover major adverse cardiovascular events in clinical trials and the impact of second-line therapies on disease control. These findings underscore AbbVie's ongoing commitment to innovation in rheumatology.

AbbVie announced results from its NOVA phase 2 study evaluating AGN-151607 for preventing postoperative atrial fibrillation (POAF) in cardiac surgery patients. Although the primary endpoint was not met, the data indicated a significant 29% relative risk reduction for CABG patients treated with 125 units. Moreover, those aged 65 and older showed a 51% risk reduction. The study also reported lower 30-day rehospitalization rates (8.7% vs. 15.7%) and more patients being atrial fibrillation-free (62.9% vs. 45.1%). Adverse events were similar across treatment groups, highlighting AGN-151607's potential in specific populations.

Allergan Aesthetics, part of AbbVie (NYSE: ABBV), expands its Pink Ribbon Strong 365 campaign, dedicated to year-round support for breast cancer patients, survivors, and previvors. The initiative emphasizes education and empowerment, offering resources like the Natrelle Cares Package and the Natrelle Inspires Bra, which donates one bra for every purchase. The campaign also includes an award-winning documentary and partnerships with organizations like METAvivor. Allergan aims to raise awareness and provide comprehensive support beyond Breast Cancer Awareness Month.